Matches in SemOpenAlex for { <https://semopenalex.org/work/W2418752813> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W2418752813 endingPage "5" @default.
- W2418752813 startingPage "451" @default.
- W2418752813 abstract "To explore the efficiency and side-effects of the combination of cyclosporine A (CsA) and thalidomide in patients with myelodysplastic syndromes (MDS).A total of thirty-seven patients with MDS-RCMD or-RAEB-I were treated with CsA in combination with thalidomide. The initial CsA dose of 3 mg×kg(-1)×d(-1) was administered, all patients had their CsA blood concentration concurrently monitored until it reached and maintained between 100 and 200 µg/L. The initial dose of thalidomide was 50 mg/d, with increasing dose of 50 mg every week until the maximum of 200 mg/d. The hematological response was assessed according to the modified criteria of the International Working Group, and adverse events were graded with the Common Toxicity Criteria (v3.0) of the National Cancer Institute. The response duration and overall survival of the patients were also observed.19/37 cases (51.4%) achieved hematologic improvement (HI)-erythroid response (HI-E), 9/29 cases (31.0%) HI-platelet response (HI-P) and 7/33 cases (21.2%) HI-neutrophil response (HI-N). 15 of 32 transfusion-dependent patients (46.9%) achieved transfusion independence. The median response duration of HI-E, HI-P and HI-N were 88 (4 - 88) weeks, 78 (8 - 84(+)) weeks and 78 (10 - 84(+)) weeks respectively. The median overall survival was 52 months on a 29 (4 - 103) months median follow-up. Some patients developed grades I-II hepatic or nephritic impairment, constipation, lethargy, dizziness, edema, rashes or numbness, and all were tolerable and reversible. No grade III or severer adverse events were observed.CsA in combination with thalidomide appears to be effective mainly in inducing HI-E and relatively well-tolerated for the treatment of patients with MDS." @default.
- W2418752813 created "2016-06-24" @default.
- W2418752813 creator A5010776860 @default.
- W2418752813 creator A5011020214 @default.
- W2418752813 creator A5016326991 @default.
- W2418752813 creator A5019377574 @default.
- W2418752813 creator A5020573943 @default.
- W2418752813 creator A5027567446 @default.
- W2418752813 date "2010-07-01" @default.
- W2418752813 modified "2023-09-22" @default.
- W2418752813 title "[Cyclosporine A in combination with thalidomide for the treatment of patients with myelodysplastic syndromes]." @default.
- W2418752813 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21122398" @default.
- W2418752813 hasPublicationYear "2010" @default.
- W2418752813 type Work @default.
- W2418752813 sameAs 2418752813 @default.
- W2418752813 citedByCount "1" @default.
- W2418752813 countsByYear W24187528132013 @default.
- W2418752813 crossrefType "journal-article" @default.
- W2418752813 hasAuthorship W2418752813A5010776860 @default.
- W2418752813 hasAuthorship W2418752813A5011020214 @default.
- W2418752813 hasAuthorship W2418752813A5016326991 @default.
- W2418752813 hasAuthorship W2418752813A5019377574 @default.
- W2418752813 hasAuthorship W2418752813A5020573943 @default.
- W2418752813 hasAuthorship W2418752813A5027567446 @default.
- W2418752813 hasConcept C126322002 @default.
- W2418752813 hasConcept C141071460 @default.
- W2418752813 hasConcept C197934379 @default.
- W2418752813 hasConcept C2776364478 @default.
- W2418752813 hasConcept C2777260799 @default.
- W2418752813 hasConcept C2779609412 @default.
- W2418752813 hasConcept C2780007613 @default.
- W2418752813 hasConcept C2780240888 @default.
- W2418752813 hasConcept C2780817109 @default.
- W2418752813 hasConcept C2780873365 @default.
- W2418752813 hasConcept C29730261 @default.
- W2418752813 hasConcept C71924100 @default.
- W2418752813 hasConcept C90924648 @default.
- W2418752813 hasConceptScore W2418752813C126322002 @default.
- W2418752813 hasConceptScore W2418752813C141071460 @default.
- W2418752813 hasConceptScore W2418752813C197934379 @default.
- W2418752813 hasConceptScore W2418752813C2776364478 @default.
- W2418752813 hasConceptScore W2418752813C2777260799 @default.
- W2418752813 hasConceptScore W2418752813C2779609412 @default.
- W2418752813 hasConceptScore W2418752813C2780007613 @default.
- W2418752813 hasConceptScore W2418752813C2780240888 @default.
- W2418752813 hasConceptScore W2418752813C2780817109 @default.
- W2418752813 hasConceptScore W2418752813C2780873365 @default.
- W2418752813 hasConceptScore W2418752813C29730261 @default.
- W2418752813 hasConceptScore W2418752813C71924100 @default.
- W2418752813 hasConceptScore W2418752813C90924648 @default.
- W2418752813 hasIssue "7" @default.
- W2418752813 hasLocation W24187528131 @default.
- W2418752813 hasOpenAccess W2418752813 @default.
- W2418752813 hasPrimaryLocation W24187528131 @default.
- W2418752813 hasRelatedWork W2081725658 @default.
- W2418752813 hasRelatedWork W2112942216 @default.
- W2418752813 hasRelatedWork W2343644536 @default.
- W2418752813 hasRelatedWork W2365897050 @default.
- W2418752813 hasRelatedWork W2372544831 @default.
- W2418752813 hasRelatedWork W2384958742 @default.
- W2418752813 hasRelatedWork W2531545753 @default.
- W2418752813 hasRelatedWork W2534309997 @default.
- W2418752813 hasRelatedWork W2538882843 @default.
- W2418752813 hasRelatedWork W2556691905 @default.
- W2418752813 hasRelatedWork W2563738770 @default.
- W2418752813 hasRelatedWork W2574432882 @default.
- W2418752813 hasRelatedWork W2581807567 @default.
- W2418752813 hasRelatedWork W2586850755 @default.
- W2418752813 hasRelatedWork W2591832575 @default.
- W2418752813 hasRelatedWork W2594147984 @default.
- W2418752813 hasRelatedWork W2594871545 @default.
- W2418752813 hasRelatedWork W2980240010 @default.
- W2418752813 hasRelatedWork W820667101 @default.
- W2418752813 hasRelatedWork W2565244756 @default.
- W2418752813 hasVolume "31" @default.
- W2418752813 isParatext "false" @default.
- W2418752813 isRetracted "false" @default.
- W2418752813 magId "2418752813" @default.
- W2418752813 workType "article" @default.